c-mos immunoreactivity is an indicator of good prognosis in lung cancer

Histopathology

Volumn 37, Issue 1, 2000, Pages 45-54

  Athanasiou, A ^c   Gorgoulis, G V ^a,c   Zacharatos, P ^a   Mariatos, G ^c   Kotsinas, A ^c   Liloglou, T ^a   Karameris, A ^c   Foukas, P ^c   Manolis, E N ^b   Field, J K ^a   Kittas, C ^c  

^a Roy Castle International Centre for Lung Cancer Research   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE

Author keywords

c mos; Lung cancer; Oncogenes; Prognosis

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CELL ONCOGENE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MOS; SURVIVAL ANALYSIS;

EID: 0006051695     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2000.00898.x     Document Type: Article

References (29)

1. 1. Minna JD. Neoplasms of the lung. In: Fauci AS, Braunwald E, Isselbacher KJ, Martin JB, eds. Harrison's Principles of Internal Medicine, 14th edn. Berkshire, UK: McGraw-Hill, 1998: 52-562.
2. 2. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochem. Biophys. Acta 1998; 1378; F21-59.
3. 3. Viallet J, Sausville EA. Involvement of signal transduction pathways in lung cancer biology. J. Cell Biochem. 1996; 24 (Suppl.); 228-236.
4. 4. Li C-CH, Chen E, O'Connell CD, Longo DL. Detection of c-mos proto-oncogene expression in human cells. Oncogene 1993; 8; 1685-1691.
5. 5. Mansour SJ, Matten WT, Hermann AS et al. Transformation of mammalian cells by constitutively active MAP kinase. Science 1994; 265; 966-970.
6. 6. Caubert JF, Matthieu-Mahul D, Bernheim A, Larsen CJ, Berger R. Human proto-oncogene c-mos maps to 8q11. EMBO J. 1985; 4; 2245-2248.
7. 7. Watson R, Oskarson M, Vande Woude GF. Human DNA sequence homologous to the transforming gene (mos) of Moloney murine sarcoma virus. Proc. Natl. Acad. Sci. USA 1982; 79; 4078-4083.
8. 8. Sagata N. What does Mos do in oocytes and somatic cells? Bioessays 1997; 19; 13-21.
9. 9. Singh B, Arlinghaus RB. Mos and the cell cycle. Prog. Cell Cycle Res. 1997; 3; 251-259.
10. 10. Choi T, Fukasawa K, Zhou R et al. The mos/mitogen-activated protein kinase (MAPK) pathway regulates the size and degradation of the first polar body in maturing mouse oocytes. Proc. Natl. Acad. Sci. USA 1996; 93; 7032-7035.
11. 11. Rhodes N, Innes CL, Propst F, Paules RS. Serum starved v-mos-transformed cells are unable to appropriately downregulate cyclins and CDKs. Oncogene 1997; 14; 3017-3027.
12. 12. Fukasawa K, Vande Woude GF. Synergy between the mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol. Cell Biol. 1997; 17; 506-518.
13. 13. Fukasawa K, Rulong S, Resau J, Pinto da Sulva P, Vande Woude GF. Overexpression of mos oncogene product in Swiss 3T3 cells induces apoptosis preferentially during S-phase. Oncogene 1995; 10; 1-8.
14. rat proto-oncogene product enhances the positive autoregulatory loop of MyoD. FEBS Lett. 1998; 437; 39-43.
15. 15. Faller DV, Mundschau LJ, Forman LW, Quinones MA. V-mos suppresses platelet-derived factor (PDGF) type-β receptor autophosphorylation and inhibits PDGF-BB-mediated signal transduction. J. Biol. Chem. 1994; 269; 5022-5029.
16. 16. Fukasawa K, Vande Woude GF. Mos Overexpression in Swiss 3T3 cells induces meiotic-like alterations of the mitotic spindle. Proc. Natl. Acad. Sci. USA 1995; 92; 3430-3434.
17. 17. Flemming ID. AJCC Cancer Staging Manual. Philadelphia: Lippincott, 1997.
18. 18. Mountain CF. A new international system for lung cancer. Chest 1986; 89(Suppl. 4); 225S-233S.
19. 19. Fukasawa K, Zhou R, Matten WT et al. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding. Oncogene 1995; 11; 1447-1457.
20. 20. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, 1980: 321.
21. 21. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials required prolonged observation of each patient. Analysis and examples. Br. J. Cancer 1977; 35; 1-35.
22. 22. Propst F, Rosenberg MP, Iyer A, Kaul K, Vande Woude GF. C-mos proto-oncogene RNA transcripts in mouse tissues: structural features, developmental regulation and localization in specific cell types. Mol. Cell Biol. 1987; 7; 1629-1637.
23. 23. Min Wang X, Yew N, Peloquin JG, Vande Woude GF, Borisy GG. Mos oncogene product associates with kinetochores in mammalian somatic cells and disrupts mitotic progression. Proc. Natl. Acad. Sci. USA 1994; 91; 8329-8333.
24. 24. Yew N, Strobel M, Vande Woude GF. Mos and the cell cycle: the molecular basis of the transformed phenotype. Curr. Opin. Genet. Dev. 1993; 3; 19-25.
25. 25. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumour suppressor gene: clues to cancer aetiology and molecular pathogenesis. Cancer Res. 1994; 54; 4855-4878.
26. 26. Chumakov AM, Miller CW, Chen DL, Koefller HP. Mutant p53 protein have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 1993; 8; 3005-3011.
27. 27. Gorgoulis V, Zacharatos P, Manolis E et al. Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene. Br. J. Cancer 1998; 77; 374-384.
28. 28. Zacharatos P, Gorgoulis V, Kotsinas A et al. Modulation of wild-type p53 activity by mutant p5 3 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53Res. of MDM2, Waf1/Cip1 and Bax genes in the lung cancer environment. Anticancer Res. 1999; 19; 579-588.
29. 29. Afshari CA, Rhodes N, Paules RS, Mudryj M. Deregulation of specific E2F complexes by v-mos oncogene. Oncogene 1997; 14; 3029-3038.